Good morning and welcome to Ocugen’s Fourth Quarter and Full Year 2022 Financial Results and Business Update Call. Please note that this call is being recorded at this time. Following the speaker's commentary there will be a Question-and-Answer Session. I will now turn the call over to Tiffany Hamilton, Ocugen’s Head of Corporate Communications. You may begin.

Thank you. Joining me today are Ocugen's Chairman, CEO and Co-Founder, Dr. Shankar Musunuri who will provide a business update and our Chief Accounting Officer and Senior Vice President of Finance, Jessica Crespo, who will provide more detail on our financial results. Earlier this morning, we issued a press release detailing business and operational highlights for the fourth quarter and full year of 2022. We encourage listeners to review the press release, which is available on our website at oxygen.com. This call is being recorded, and a replay of the accompanying slide presentation will be available on the Investors section of the Ocugen website for approximately 45 days. This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as predict, believe, potential, propose continue, estimate, anticipate, expect, plan, intend, may, could, might, will, should or other words that convey uncertainties of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks and uncertainties that may cause actual events or results to differ materially from our current expectations. Investors should familiarize themselves with the company's filings for complete details. Except as required by law, we assume no obligation to update forward-looking statements contained in this presentation. whether as a result of new information, future events or otherwise after the date of this presentation. Finally, Ocugen's 10-K covering 2022 will be filed soon after today's call. I will now turn the call to Dr. Musunuri.

Thank you, Tiffany. Good morning, and thank you all for joining us today. I'm excited to share with you the significant progress Ocugen made in 2022 and during the first months of 2023 to further advance our diversified pipeline while continuously focusing on patients and pursuing courageous innovation, fueled by our team's passion, dedication and visionary mindset, we witnessed progress across all our clinical programs. I will also provide more on our objectives for 2023, leading into 2024. We -- let me commence with an update on our gene therapy program. In December 2022, we announced that Q400, our investigational drug candidate for the treatment of retinitis pigmentosa and Leber congenital amaurosis was granted expanded orphan drug designations by the U.S. FDA, which supports the therapeutic potential of our Q400 to treat multiple inherited retinal diseases, the single product. AC400 is symbolic of Ocugen’s gene modifier approach that is based on nuclear hormone receptors that regulate diverse physiological functions in the retina, such as development, metabolism, cellular functions and thereby establishes homeostasis to potentially restore retinal health and function. In the U.S., RP and LCA effect 110,000 and 15,000 people, respectively. And globally, these conditions affect approximately 1.6 million people. And at despite its prevalence, RP and LCA patients have limited treatment options. As current approved or in development gene therapies focus on individual genes, RQ400 addresses shortcomings of current gene therapy approaches as a broad spectrum gene agnostic approach to genetically diverse inherited retinal diseases. We have completed enrollment of RP patients in the Phase I/II trial for protocol and continue to enroll patients with LCA. We also established the high dose to be the maximum tolerable dose. We plan to start the Phase III clinical trial near the end of 2023. ARQ 200, our biologic product candidate is…

Thank you, Shankar, and good morning, everyone. I will now provide a brief overview of our key financial results for the fourth quarter and full year 2022. Our research and development expenses for the quarter ended December 31, 2022, were $17.2 million compared to $7.1 million for the fourth quarter of 2021. For the full year ended December 31, 2022, research and development expense was $49.8 million compared to $35.1 million for the year ended December 31, 2021, with the increase primarily driven by the advancement of our product candidates into clinical trials. General and administrative expenses for the fourth quarter ended December 31, 2022, were $6.9 million compared to $7.5 million for the fourth quarter of 2021. General and administrative expenses for the full year 2022 were $35.1 million compared to $22.9 million for the year ended December 31, 2021. Net loss was approximately $21.9 million or $0.10 net loss per common share for the quarter ended 2022 Q4 compared to a net loss of approximately $14.6 million or $0.07 net loss per share for the fourth quarter of 2021. Full year net loss was $81.4 million or $0.38 net loss per share compared to a net loss of $58.4 million for the full year of 2021 or $0.30 net loss per share. Our cash, cash equivalents and investments totaled $90.9 million as of December 31, 2022, compared to $95.1 million as of the year ended December 31, 2021. We expect that our cash, cash equivalents and investment balance will enable us to fund operations into the first quarter of 2024. We're continuously exploring opportunities to increase our working capital, and we'll be focused on seeking out partnerships and nondilutive funding, as Shankar mentioned during his prepared remarks. That concludes my update for the quarter. Tiffany, back to you.

Thanks, Jeff. We'll now open the call for questions. Operator?

[Operator Instructions] Our first question will come from the line of Uy Ear with Mizuho Securities.

I was wondering if you could sort of speak a little bit about your -- some more about the COVID program, particularly with COVAXIN, could you sort of just help us understand where -- how it fits currently, I guess, within the changing landscape where the FDA, I guess, are moving forward with recommendations for bivalent and as well as companies developing as you guys are also with the 200 Series in combination with the flu vaccine? That's my first question. And I guess my second question is on our Q400, could you sort of help us understand as you -- what should we expect, I guess, from the Phase II readout in midyear? And how would that help you to move into Phase III in terms of, I guess, trial designs as well as what sort of primary endpoint you would propose to the FDA.

Thank you. Starting with the co-vaccine, first question to address, yes, the market landscape is moving, obviously. And we -- as we stated before, we're anticipating the full data analysis by midyear. And obviously, COVAXIN is a good vaccine. I mean, this has got solid data. It is given to a few hundred million people across the globe. The favorable safety profile. And unfortunately, in U.S., we needed to do more work to bridge with U.S. demographic and population as stated by FDA. So the first trial obviously included immune-bridging trials. That's what we're completing. And the second one, obviously, we are anticipating a safety trial because you need to bridge immune-bridge to efficacy, the large efficacy trial done over by partners in India. And the second step is, of course, the safety bridge. And as we stated earlier, we needed to work with government agencies. Having more vaccine opens is important in this -- especially with a favorable safety profile, we confirmed in our immune-bridging trial, we didn't have any myocardiac pericarditis or thromboses, any of the adverse events like you see with other vaccines. And again, consistently confirming the safety data generated by our partners elsewhere. So we believe this has a space provided we do get some help and funding from the government. So that's where the co-vaccine, I mean, as I stated before, there's more work to be done. Obviously, there's a need for multiple tools in the toolkit. -- acuity is not done. It will be there for many years. And we believe with a favorable safety profile, vaccine, which is built on a traditional vaccine platform such as Folio and other vaccines. This could be a vaccine in a toolkit, which could be beneficial for many patients or many subjects. Now coming to OCU400.…

Your next question comes from the line of Jennifer Kim with Cantor Fitzgerald.

I have a few here. I guess the first one is OCU200. I saw that you're going to get the Phase I started up, and we're going to see some initial data in the fourth quarter. And I'm wondering what should -- what are you looking for in that preliminary data? And how should we think about the design of that trial? And then second, I think you mentioned that your runway gets you to the first quarter of 2024. I'm wondering how do you think about -- I think previously it was runway into the end of this year. And I'm wondering, I guess, where -- how should we think about like how you're managing cash as you're balancing all these programs and how you're able to extend that?

Yes. 200, as we announced, it's a dose escalation study. in a small population or goes to look at the range of doses, and so we can pick one before we go into Phase II. So as a part of that, I mean, obviously, we're going to look at CST, central soft field thickness as other companies have looked at from DME space specifically. Once again, the primary objective of any Phase I clinical trial is safety as a part of the dose escalation to finalize the dose. And we'll be looking at observational endpoints and one of them is ST. And now the second question, extending runway into Q1. I'll let Jess answer that.

Sure, Jennifer. So in terms of the extension of our runway into the first quarter, we did utilize our ATM a bit. So that has helped us extend our runway into Q1 of 2024. But as Shankar mentioned, I mean we will need to raise capital in order to progress on all of our programs, and we're exploring many different options, including our focus on nondilutive funding, as we stated.

Okay, great. And maybe if I could squeeze one more question. With the 2 additional IND filings in the second quarter of this year, should we think about you -- or initiation of those clinical programs? Could that come this year? Or are you thinking more in, I guess, early next year?

As we stated -- yes -- yes, yes. Again, I just wanted to confirm. The Fortuna for is, we call it, we separated it out because 410 targets dry age-related macular degeneration, specifically will be targeting late-stage patients in geographic atrophy, and that's targeted for filing in second quarter of this year. Similarly, our Q4 ST targeting orphan disease [indiscernible] is also targeted for second quarter of this year, IND filing.

Your next question will come from the line of Jonathan Aschoff with ROTH MKM [ph].

Most have been answered, but did you say the NeoCart trial would start in the fourth quarter of next year or just some time next year?

No. Actually, we stated Nicotine will start first half of next year. We are constructing CGMP manufacturing facility, and that will be complete by the end of this year.

Okay. And can you give us a little more clarity on how much is left on the ATM as of today?

Yes. So as part of our, I would say, general corporate housekeeping, we've canceled the ATM in connection with converting our automatic shelf into a regular shelf. So you'll see those filings come through today. So we'll put the ATM back up when and if it's appropriate for the appropriate amount. So at this point, it's in capital.

Okay. But can you tell us how much of that ATM was actually used overall from the core and in it?

Yes. Under that ATM, we've sold approximately $14 million in terms of gross proceeds, and we've netted about $13.6 million.

Yes, that is all.

Your next question comes from the line of Robert LeBoyer with Noble Capital Markets.

Thank you for laying out some of the milestones for the COVAXIN [ph] programs. Could you give any time frames for–- well, you had mentioned the midyear top line or conclusions in full data. Could you give some of the time frames for the Phase III and some of the other program starts and milestones?

Robert, are you specifically referring to COVAXIN [ph] or other programs.

Are you referring to co vaccine and other programs?

Yes.

As I stated before, Yes. The vaccine, we are finishing up the current study, and we'll have the final data analysis expecting midyear this year. And as I stated before, we may need to do a safety clinical trial. We're still waiting for BA to respond their comments on our safety protocol. And once we get that, obviously, we -- as we stated, we are seeking government funds to conduct the clinical trial. So as far as other Phase III clinical trials are concerned, there are 2 more we talked about during this earnings call. One of them is our signature ARK400 modified gene therapy platform. So where we have completed recruitment in our retinitis pigmentosa portion of the Phase I/II clinical trial. And so based on data read, we're anticipating midyear on efficacy signal. And we're going to get into -- planning to get into Phase III by the end of this year for RQ400 gene therapy Phase III clinical trial. And the second Phase III clinical trial is related to NeoCart, our cell therapy platform, -- and the rate limiting for that is – it’s a colo-cell [ph] therapy. It’s almost like a personalized medicine. So we are building our own manufacturing facilities, runway in the existing facilities to convert them into cGMP manufacturing for cell therapy production. And we’re anticipating that construction will be complete by the end of the year, and that will allow us to initiate Phase III clinical trial in the first half of 2024.

Your next question will come from the line of Sean Lee with H.C. Wainwright.

Just a quick question from me. So for the proposed new CAR study, have you finalized on the endpoint in the study design yet?

Yes. I think the study design, as we agreed with the DA includes chondroplasty as a control, and that's different than prior control they used in the prior studies. The second thing is the endpoints will include pain and function.

Compared to the previous Phase III that histogenics ramp with NeoCart, what would be the key differences?

The key differences are -- they had a microfracture control, which is -- I mean, so what we did is we looked into the current standard of care, which is chondroplasty. And so based on that, we actually wanted to use chondroplasty and FDA is that. The second thing is we're also going to restrict the lesion size to the 3 Centimeter Square and really focus on that so that it's not very broad like they did before. So I think with these changes, we anticipate we'll have better prospects of relatively easily recruiting patients. That's important because chondroplasty is standard of care, not for microfracture. And that's really important. That's an important change. And also focusing on a specific range for lesion size is very important for us.

Great. One last final follow-up on that. For the new manufacturing facility that you’re building, would that be only for supporting materials for the Phase III? Or could you scale that up to potential commercial later as well?

Good questions, Sam. When we build this personalized medicine, many cell therapies, this is like a scale-out mark scale-up. So these are very small -- you can call them bioreactors. We call them tissue-engineer process units hep. So these things are very small suites. So this can be used for commercial manufacturing to...

I see. That’s all the questions I have.

Your next question will come from the line of Daniil Gataulin with Chardan.

Congrats on all the progress. Just a couple of follow-ups, one on the cash runway in terms of bundling. Are you expecting to fund the OC 500 series Lexin [ph] programs internally or look for external funding? That's one. And two, in relation to 1010, the 2 INDs that you plan to file this year, are you planning to initiate the actual trials this year as well? Or are you planning to initiate those in 2024?

The first one is related to Q500 Series emulation vaccines. So as we stated before, we are funding the development of those vaccines and taking it to the clinic. So we're also in parallel working with various government agencies because of the need, we believe we are trying to secure funding from them. So we do need their support to move them into the clinic. But the development part and preclinical studies, we have budgeted for it and we're going to complete that -- and the second question you had on Q4 10 and OCU410 SD targeting dry AMD and Stroer [ph] disease. Those INDs are scheduled to be filed planning in the second quarter of this year. And as soon as we get a positive amount from FDA, we will start dosing patients this year.

This concludes the Q&A portion. I will now turn the call back over to Chairman and CEO, Dr. Shankar Musunuri.

Thank you, operator. I'd like to conclude the call with some additional remarks. I think it's clear that we are staying true to our mission as an integrated patient-centric biotechnology company that targets unmet medical needs. We believe we are in a position of strength, and we are poised to execute our goals with our pipeline for the course of 2023. We look forward to keeping you updated on our programs throughout the year. Thanks for your time today, and have a great week.

Thanks, everyone. Have a great day.

Thank you all for joining today's meeting. You may now disconnect.